Clinical trial
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
ClinicalTrials.gov ID: NCT03535194
Sponsor: Eli Lilly and Company
Information provided by: Eli Lilly and Company (Responsible Party)
Last Update Posted: 2021-03-30
Brief Summary:
The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.
Official Title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Intervention / Treatment:
- Drug: Mirikizumab
- Drug: Placebo
- Drug: Secukinumab
| Category | Value |
|---|---|
| Study Start (Actual) | 2018-06-26 |
| Primary Completion (Actual) | 2020-03-05 |
| Study Completion (Actual) | 2020-06-03 |
| Enrollment (Actual) | 1484 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
16504
I6T-MC-AMAJ (Other Identifier) (OTHER: Eli Lilly and Company) 2017-003286-10 (EudraCT Number) |